Align Financial’s Bristol-Myers Squibb BMY Stock Holding History

Align Financial’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$811	Buy	+13	New	+$822	﹤0.01%	422

Other funds holding BMY

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Align Financial's BMY Position: Q3 2026 in Review

Align Financial opened a new position in Bristol-Myers Squibb (BMY) in Q3 2026: 13 shares worth $811. The stake represents ﹤0.01% of the portfolio and ranks #422 among its holdings.

623 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

Align Financial held 13 shares of Bristol-Myers Squibb worth $811 as of Q3 2026.
Bristol-Myers Squibb was a new Align Financial position in Q3 2026.
Bristol-Myers Squibb made up ﹤0.01% of Align Financial's portfolio in Q3 2026, its #422 holding.
623 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Align Financial's 13F filing for Q3 2026, filed 16 Oct 2026.